Older mitochondrial uncoupling agents could not distinguish between mitochondrial and p…
These are novel small-molecule compounds designed to act as 'mitochondrial uncouplers' — essentially, they make cells burn energy less efficiently, dissipating it as heat rather than storing it. Critically, they are engineered to act selectively inside mitochondria without disrupting the broader cell membrane, which was the fatal flaw of earlier uncouplers like DNP. This selectivity makes them potentially safe candidates for treating a wide range of conditions tied to metabolic dysfunction and oxidative stress, including obesity, type 2 diabetes, NASH, certain cancers, and neurodegenerative diseases like Parkinson's. The patent covers a broad chemical scaffold with extensive structural variation, giving the inventors significant design space for optimization.
What you could build
A first-in-class oral drug candidate for metabolic diseases — particularly NASH/NAFLD and obesity — that works through a mechanism distinct from GLP-1 agonists and SGLT2 inhibitors; target buyers would be pharmaceutical companies or biotech firms building metabolic disease pipelines.
Who in Virginia should care
Pharma and biotech companies with mid-Atlantic R&D operations, or Virginia-based contract research organizations supporting IND-enabling studies, would be natural licensing or partnering candidates.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Webster L. Santos, Joseph Michael Salamoun, Christopher J. Garcia, Jacob H. Murray
- Granted
- June 16, 2026
- Status
- Granted patent
- Patent number
- 12655156
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.